AI Article Synopsis

  • The influenza vaccine is widely used and generally safe, but very rare serious side effects can occur, like myositis, as seen in a reported case.
  • A 77-year-old man developed muscle weakness in his legs after receiving the vaccine, and treatment with high-dose steroids led to a full recovery.
  • Despite the lack of a clear link between the vaccine and his condition, it's important to monitor such rare events to improve vaccine safety, while still encouraging vaccination due to its overall benefits.

Article Abstract

The influenza vaccine is one of the most commonly administered vaccines worldwide, with a high safety profile. However, rare cases of serious adverse events have been reported in the literature. We report a 77-year-old male who presented with progressive weakness in the lower extremities shortly after receiving the Influenza vaccine. He was diagnosed with myositis involving the paraspinal and bilateral lower extremity muscles. He received treatment with high-dose steroids and taper with full recovery of his muscle weakness. Although the exact causal mechanism between the vaccine and the patient's myositis could not be established, surveillance for such rare adverse events can provide data for future vaccine safety improvement. Due to well-known benefits of the Influenza vaccine that far exceed the potential adverse effects, we strongly encourage the readers to continue their vaccine practices as per CDC guidelines.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11259473PMC
http://dx.doi.org/10.55729/2000-9666.1330DOI Listing

Publication Analysis

Top Keywords

influenza vaccine
12
adverse events
8
vaccine
6
rare case
4
case toxic
4
toxic myositis
4
myositis associated
4
influenza
4
associated influenza
4
influenza vaccination
4

Similar Publications

College students have cited inconvenience, ease of forgetting, and lack of time as barriers to influenza (flu) vaccine receipt. We hypothesized that "pop-up" clinics and live-attenuated influenza vaccine (LAIV) would facilitate delivery and align with preferences of college students. During the 2023-2024 flu season, undergraduate participants were recruited to receive LAIV at 5 "pop-up" clinics across a large midwestern campus.

View Article and Find Full Text PDF

Background: Patients with congenital heart defects (CHDs) are at higher risk for infectious diseases. This may partly be due to frequent hospital stays and the associated exposure to pathogens. This study aims to provide a comprehensive overview of immunisation coverage among twins in which at least one twin has CHD.

View Article and Find Full Text PDF

Background: Seasonal influenza illness and acute respiratory infections can impose a substantial economic burden in low- and middle-income countries (LMICs). We assessed the cost of influenza illness and acute respiratory infections across household income strata.

Methods: We conducted a secondary analysis of data from a prior systematic review of costs of influenza and other respiratory illnesses in LMICs and contacted authors to obtain data on cost of illness (COI) for laboratory-confirmed influenza-like illness and acute respiratory infection.

View Article and Find Full Text PDF

Respiratory syncytial virus (RSV) causes a substantial health burden among infants and older adults. Prefusion F protein-based vaccines have shown high efficacy against RSV disease in clinical trials, offering promise for mitigating this burden through maternal and older adult immunization. Employing an individual-based model, we evaluated the impact of RSV vaccination on hospitalizations and deaths in 13 high-income countries, assuming that the vaccine does not prevent infection or transmission.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!